KEYNOTE-B96 Trial Shows Keytruda is First Immunotherapy to Improve Overall Survival in Platinum-Resistant Ovarian Cancer
Credit: MohammedElAmine | stock.adobe.com Key Takeaways from the Phase III KEYNOTE-B96/ENGOT-ov65 Trial Keytruda Shows First OS Benefit in Ovarian Cancer:…
